A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects

NCT00002353 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: P3C541b Lipopeptide

Sponsor

United Biomedical